208 related articles for article (PubMed ID: 36094370)
1. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract][Full Text] [Related]
2. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
3. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
4. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
[TBL] [Abstract][Full Text] [Related]
8. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
9. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
[TBL] [Abstract][Full Text] [Related]
10. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
11. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
12. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
13. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
Loh ML
Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
[TBL] [Abstract][Full Text] [Related]
14. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
16. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
[TBL] [Abstract][Full Text] [Related]
17. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
[TBL] [Abstract][Full Text] [Related]
18. After 95 years, it's time to eRASe JMML.
Meynier S; Rieux-Laucat F
Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
[TBL] [Abstract][Full Text] [Related]
19. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
Chang TY; Dvorak CC; Loh ML
Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
[TBL] [Abstract][Full Text] [Related]
20. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]